None listed
Conditions
Interventions
Intervention1: Liposomal Nicotinamide Mononucleotide Formulation(125 mg): Single oral dose.
Control Intervention1: Conventional Nicotinamide Mononucleotide
Sponsors
Molecules Biolabs Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1. Normal, healthy, adult, male and female Human participants of age between 18-45 years with a Body Mass Index (BMI) range between 18.50 kg/m2 to 24.99 kg/m2. 2. Subject agrees avoid NMN containing medications and dietary supplements from screening until last visit. 3. Subject agrees to avoid high activity physical exercise 72.00 hours prior to last visit 4. Subjects who have no evidence of underlying disease during screening and check- in and whose screening is performed within 29 days of check in. 5. Subjects generally healthy as documented at screening considered by the physician or principal/clinical investigator. 6. Healthy as documented by the medical history, physical examination (including but may not be limited to an evaluation of the cardiovascular, gastrointestinal, respiratory, musculoskeletal and central nervous systems) and vital sign assessments. 7. Non- smokers or ex-smokers. Ex-smokers are defined as someone who has completely stopped smoking for at least the past 03 months. 8. Willing to consume ova-lacto vegetarian diet. 9. Willing to comply to all requirements of this study protocol as well as instructed by the study personnel 10. Generally healthy as documented by gynecological examination and breast examination (for female subjects during Period-I check-in only). 11. Female subjects of childbearing potential. a. Practicing an acceptable non-hormonal contraceptive method of birth control after consulting with principal investigator; and/or b. Surgically sterile (bilateral tubal ligation)
Exclusion criteria
Exclusion criteria: 1. Evidence of allergy or known hypersensitivity to NMN or other related drugs or other related drugs. 2. Subjects with hepatic encephalopathy, cholestasis, myasthenia, pre-existing liver disease, alcohol abuse, existing tinnitus, renal or liver impairment and pre-existing gallbladder disease. 3. Any major illness in the last three months or any significant ongoing chronic medical illness. 4. Any disease or condition which might compromise the haemopoeitic, gastrointestinal, renal, hepatic, cardiovascular, Musculoskeletal, respiratory, central nervous system, diabetes, psychosis or any other body system. 5. History of alcohol addiction or abuse. 6. Malabsorption syndrome that affects NMN metabolism. 7. Heart failure, angina pectoris, ventricular arrhythmias or atrial fibrillation with more than 100 per min ventricular rate. 8. Gastrointestinal bleeding in past three months. 9. Uncontrolled diabetes mellitus. 10. Active psychiatric disorder, intention for suicidal, disorders with Unconsciousness. 11. Psychopathic disorder, lack of cooperation. 12. Chronic obstructive lung disease or active smoking (more than 2 cigarettes in the past 6 months) 13. Taking more than 125 mg NMN daily within 2 weeks to screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the oral bioavailability of investigational product of Molecules BioLabs Private Limited, in comparison with the reference product conventional NMN of Molecules BioLabs Private Limited in healthy, adult, human subjects under fasting conditions.Timepoint: day1. | — |
Secondary
| Measure | Time frame |
|---|---|
| To monitor the adverse events and to ensure the safety of the subjects.Timepoint: Day1 through End of study. | — |
Countries
India
Contacts
Public ContactShalini Dayananda
Unitree Health Care Diagnostics
Outcome results
None listed